Dramatic response to panitumumab and bevacizumab in metastatic gallbladder carcinoma.

This letter reports on a dramatic response to panitumumab and bevacizumab in a patient with widespread metastatic gall bladder carcinoma.

[1]  Yun Yen,et al.  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer , 2009, Cancer Chemotherapy and Pharmacology.

[2]  P. Philip,et al.  Phase II study of erlotinib in patients with advanced biliary cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Y. Yen,et al.  Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.